For example, pembrolizumab is assessed by 22C3 antibody (Dako)2,20; nivolumab by 28-8 (Dako)21; atezolizumab by SP142 (Ventana Medical Systems)10; and durvalumab by SP263 (Ventana Medical Systems).22,23 The Blueprint PD-L1 IHC Assay Comparison Project revealed that the sensitivity of PD-L1 staining on tumor cells by 22C3, 28-8, and SP263 were comparable, whereas the SP142 assay exhibited a weaker staining,24 which was also observed in another study.25 The gene discussed is CD274; the disease is neoplasm.